About milrinone
Phosphodiesterase-3 inhibitor; inotrope and vasodilator
Used for
- Short-term treatment of severe heart failure in monitored hospital settings
Usual adult dose
Intravenous loading dose 50 micrograms/kg over 10 minutes, then infusion 0.375–0.75 micrograms/kg/min; adjust for kidney function.
Usual dose in children
Specialist-directed intravenous infusion; dosing varies by age and condition. Not for routine use.
Common side effects
- Low blood pressure
- Abnormal heart rhythms
- Headache
- Low platelet count
Important warnings
- Requires continuous blood pressure and heart-rhythm monitoring.
- Kidney impairment can increase drug exposure; dose reduction may be needed.
- Long-term or repeated use may increase risk of serious heart problems.
- Intravenous administration can cause local irritation or tissue injury if leaked.
Pregnancy
Use only when clearly needed; human pregnancy safety information is limited.
Breastfeeding
Unknown whether milrinone enters breast milk; use requires clinical assessment.
Interactions
- Other blood-pressure-lowering medicines may increase low blood pressure.
- Medicines affecting heart rhythm may increase arrhythmia risk.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.